Dr Reddy’s Laboratories shares fall nearly 2% on acquiring Johnson & Johnson’s Stugeron brand

This comes after the company entered a definitive agreement with Johnson & Johnson affiliate Janssen Pharmaceutica NV (JPNV) to acquire the Stugeron brand for $50.5 million or approximately ₹445 crore.

The pharmaceutical will acquire Stugeron’s leading brands, including Stugeron FORTE and Stugeron PLUS, as well as its related assets (STUGERON portfolio) across 18 markets in the Asia-Pacific (APAC) and Europe, the Middle East, and Africa (EMEA) regions, with India and Vietnam being its key markets, Dr Reddy’s said in a regulatory filing dated September 10.

With this, Dr. Reddy’s Laboratories also acquired the anti-vertigo drug Cinnarizine, which, to be specific, is an antihistamine indicated for the treatment of vestibular disturbances and vertigo.

STUGERON holds the first position in the Cinnarizine represented the pharmaceutical market (RPM) and is ranked second in the anti-vertigo extended represented pharmaceutical market (eRPM) in India.

Thus, this acquisition presents a strategic opportunity for Dr Reddy’s to expand its footprint in the anti-vertigo space and strengthen its Central Nervous System (CNS) portfolio.

Commenting on the acquisition, M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddy’s, said: “Dr. Reddy’s acquisition of the STUGERON brand reflects a steady advancement in our efforts to expand into the anti-vertigo therapeutic segment, contributing to the continued development of our CNS portfolio.”

“Backed by our strong market access, we intend to extend the reach of STUGERON® and its associated products across 18 key markets in the APAC and EMEA regions, including India and Vietnam. This strategic step is in line with our broader commitment to improving patient access and advancing toward our goal of reaching over 1.5 billion patients by 2030,” Ramana added.

At around 11:19 am, the stock was trading 0.71% lower at ₹1,295 per equity share.

While the scrip reached a year’s low of ₹1,020 on April 7, 2025, it touched a 52-week high of ₹1,405.90 on January 8, 2025.

Dr. Reddy’s Laboratories has a total market capitalisation of ₹1.08 lakh crore, as of September 11, 2025, according to data on the NSE.